Development Pipeline Progress Status





Cautionary Notes

Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable.

Actual performance and other results may differ significantly due to various factors. Such factors include, but are not limited to:


- (*i*) failures in new product development
- (*ii*) changes in general economic conditions due to reform of medical insurance system
- (*iii*) failures in obtaining the expected results due to effects of competing products or generic drugs
- (*iv*) infringements of the Company's intellectual property rights by third parties
- (*v*) stagnation of product supply from the delay in production due to natural disasters, fires and so on
- (vi) onset of new side effect of post-licensure medical product

and, (vii) currency exchange rate fluctuations and interest rate trend.

Information about pharmaceutical products (including products currently in development) included in this document is not intended to constitute an advertisement of medical advice.



Plan for Submissions in Japan



As of Apr 26, 2022



Development status of OPDIVO (1)

As of Apr 26, 2022

Target disease	Line of Therapy	Treatment	Japan	Korea	Phase Taiwan	US	EU
Melanoma	Adjuvant • 1st • 2nd	Monotherapy, with lpi (1 st line only)	Approved	Approved	Approved	Approved	Approved
	Neo-adjuvant	with Chemo	Filed			Approved	Filed
		with lpi	Approved	Approved	Approved	Approved	_
Non-small cell	_	with lpi + Chemo	Approved	Approved	Approved	Approved	Approved
lung cancer	1st	with Chemo	Approved	_	_	_	—
		with Chemo (NSQ)	Revision of labeling	Approved	Approved	_	_
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
	Adjuvant	with lpi	III	_	_	III	III
	1st	with lpi	Approved	Approved	Approved	Approved	Approved
Renal cell carcinoma		with TKI	Approved	Approved	III	Approved	Approved
		with lpi + TKI	_	III	III	III	III
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Hodgkin's	Relapsed /Refractory	with Brentuximab		_	_	III	_
lymphoma		Monotherapy	Approved	Approved	Approved	Approved	Approved
Head and neck cancer	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
Malignant pleural	1st	with lpi	Approved	Approved	Approved	Approved	Approved
mesothelioma	SOC refractory	Monotherapy	Approved	_	_		_

Red: Update after May 2021



Development status of OPDIVO (2)

As of Apr 26, 2022

Target	Line of Treatment	Phase					
disease	Therapy	i reatinent	Japan	Korea	Taiwan	US	EU
Gastric cancer	Adjuvant	with Chemo	III	III	III	_	_
	1st	with Chemo	Approved	Approved	Approved	Approved	Approved
		with lpi + Chemo	=	III	III	_	_
	3rd	Monotherapy	Approved	Approved	Approved	_	_
	Adjuvant	Monotherapy	Approved	Approved	Approved	Approved	Approved
Esophageal cancer	1st	with Ipi, with Chemo	Filed	Ш	Ш	Filed	Approved
	2nd	Monotherapy	Approved	Approved	Approved	Approved	Approved
	1st	with Chemo	II / III	_	_	/	II / III
Colorectal	MSI-H/dMMR (1st)	with lpi	Ξ	_	_	III	III
cancer	MSI-H∕dMMR	Monotherapy	Approved	_	Approved	Approved	-
	(3rd)	with lpi	Approved	Approved	Approved	Approved	Approved*
Hepatocellular carcinoma	Adjuvant	Monotherapy	III	III	III	III	III
	1st	with lpi	III	III	III	III	III
	2nd	Monotherapy, with lpi	Π	II	Approved**	Approved**	II

* 2nd line

* With Ipi (US), Monotherapy only (Taiwan)



Development status of OPDIVO (3)

As of Apr 26, 2022

Target	Line of Treatment Therapy	Phase					
disease		Treatment	Japan	Korea	Taiwan	US	EU
	Perioperative	with Chemo	Ш	III	III	III	Ш
Urothelial cancer	Adjuvant	Monotherapy	Approved	Approved	Approved	Approved	Approved
/ Bladder cancer	1st	with lpi, with Chemo	Ш	Ш	Ш	III	Ш
	2nd	Monotherapy	II	Approved	Approved	Approved	Approved
Ovarian cancer	1st	with Rucaparib	III	III	III	III	III
castration- resistant prostate cancer	1st or 2nd	with Chemo	111	111	111	111	Ш
Pancreatic cancer	1st	with Chemo	II	П	П	_	_
Virus positive / negative solid carcinoma	Neo-adjuvant, $1 ext{st} \sim 3 ext{rd}$	Monotherapy, with lpi (1st~3rd only)	1/11	1 / 11	1 / 11	1 / 11	1 / 11
Cancer of unknown primary	_	Monotherapy	Approved	_	_	_	_
	240 mg(every 2 weeks)	Approved	Approved	III	Approved	Approved
Dosage and Administration	360 mg (every 3 weeks)		Approved	Approved	Approved	Approved	Approved
	480 mg (every 4 weeks)	Approved	Approved	III	Approved	Approved



Clinical trials in combination therapy OPDIVO & other Immuno-Oncology compounds

As of Apr 26, 2022

Development code (Generic name) Pharmacological action	Cancer type	Japan	US/EU	KR/TW
ONO-4686 Anti-TIGIT antibody	Solid tumor	/	1 / 11	-
ONO-4482 (Relatlimab) Anti-LAG-3 antibody	Melanoma	/	Approved★	-
	Solid tumor, Gastric cancer	I	1 / 11	-
ONO-4578	Colorectal cancer	I	-	-
PG receptor (EP4) antagonist	Pancreatic cancer	I	-	-
	Non-small cell lung cancer	I	-	-
ONO-7475 AxI/Mer inhibitor	Solid tumor	I	-	-
ONO-7913 (Magrolimab)	Pancreatic cancer	I	-	-
Anti-CD47 antibody	Colorectal cancer	I.	-	-
ONO-7119 (Atamparib) PARP7 inhibitor	Solid tumor	I.	-	-
ONO-7122 TGF-βinhibitor	Solid tumor	I	-	-
ONO-7914 STING agonist	Solid tumor	I	-	-

★ : fixed-dose combination of nivolumab and relatlimab(US) Red: Update after May 2021



Development pipeline in Japan (Oncology area other than OPDIVO)

As of Apr 26, 2022

Product name/ Development code (Generic name)	Target indication	Pharmacological action				
【PhaseIII】						
ONO-7913 (Magrolimab)	TP53-mutant Acute myeloid leukemia	Anti-CD47 antibody				
[Phase II]						
BRAFTOVI (Encorafenib)	BRAF-mutant thyroid cancer	BRAF inhibitor				
MEKTOVI (Binimetinib)	BRAF-mutant thyroid cancer	MEK inhibitor				
[Phase I]						
	Solid tumor, Gastric cancer *					
	Colorectal cancer *					
ONO-4578	Pancreatic cancer *	PG receptor (EP4) antagonist				
	Non-small cell lung cancer *					
	Hormone receptor-positive, HER2-negative breast cancer					
	Solid tumor *					
ONO-7475	EGFR mutation-positive non-small cell lung cancer	AxI / Mer inhibitor				
	Solid tumor					
ONO 7012 (Magralimah)	Myelodysplastic syndrome	Anti CD17 antibady				
ONO-7913 (Magrolimab)	Pancreatic cancer *	Anti-CD47 antibody				
	Colorectal cancer *					

* Combination with Opdivo. Red: Update after May 2021



Development pipeline in Japan (Non-oncology)

As of Apr 26, 2022

Product name/ Development code (Generic name)	Target indication	Pharmacological action	
[Filed]			
ONOACT (Landiolol hydrochloride)	Tachyarrhythmia in low cardiac function <pediatric></pediatric>	Short-active selective β_1 blocker	
[PhaseIII]		<u>.</u>	
ONO-2017 (Cenobamate)	Primary generalized tonic-clonic seizures	Inhibition of voltage-gated sodium currents/positive	
	Partial-onset seizures	allosteric modulator of GABA _A ion channel	
VELEXBRU (ONO-4059:Tirabrutinib)			
[Phase II]			
ONO-2910	Diabetic polyneuropathy	Schwann cell differentiation promoter	
【Phase I】			
VELEXBRU (ONO-4059:Tirabrutinib)	Generalized scleroderma	BTK inhibitor	
ONO-4685	Autoimmune disease	PD-1 $ imes$ CD3 bispecific antibody	
ONO-2909	Narcolepsy	PG receptor (DP1) antagonist	
ONO-2808	Neurodegenerative diseases	S1P5 receptor agonist	



Global devlopment projects (Other than OPDIVO)

As of Apr 26, 2022

AS OF APT 26, 2022							
Product name/ Development code (Generic name)	Target indication	Pharmacological action	Area				
[Approved]							
BRAFTOVI (Encorafenib)	BRAF-mutant colorectal cancer	BRAF inhibitor	KR				
VELEXBRU	Primary central nervous system	BTK inhibitor	KR				
(ONO-4059:Tirabrutinib)	lymphoma		TW				
【PhaseIII】							
ONO-7913 (Magrolimab)	Acute myeloid leukemia	Anti-CD47 antibody	KR·TW				
【Phase II 】							
ONO-4059 (Tirabrutinib)	Primary central nervous system lymphoma	BTK inhibitor	US				
(Phase I / II)							
ONO-7475	Acute leukemia	AxI / Mer inhibitor	US				
【Phase I】							
ONO-7684	Thrombosis	FXIa inhibitor	EU				
ONO-2808	Neurodegenerative disease	S1P5 receptor agonist	EU				
ONO-4685	T-cell lymphoma PD-1 x CD3 bispec		US				
	Autoimmune disease	antibody	EU				



ONO PHARMACEUTICAL CO.,LTD.

Dedicated to the Fight against Disease and Pain